AbbVie Discovery Series

The hepatitis C medical revolution

Find Out More

23 July, 2019

AbbVie welcomes Therapeutic Goods Administration (TGA)
Regulatory Approval of SKYRIZI™ (risankizumab)

20 June, 2019

AbbVie ANZ Appoints New Medical Director

24 February, 2019

New targeted treatment option for patients with Chronic Lymphocytic Leukaemia (CLL) now available on the Pharmaceutical Benefits Scheme

By putting patients first, we explore new medical innovations and ways to enhance access

Patients

The Medicines Ecosystem

Helping to Eliminate HCV in Australia by 2030

All Stories

Our approach to innovation builds on strong science combined with the drive to find solutions where the need is the greatest

Our Science

$24 million

invested by AbbVie in Australian medical research and clinical trials in 2017

Passionate about our work, responsible in our actions—we go beyond medicine to improve health care and our communities

Responsibility

AbbVie combines advanced science, expertise and passion to solve the world’s most serious health issues and have a remarkable impact on people’s lives

Our Company

31,000+

people treated by AbbVie medicines in Australia

20+

conditions treated across infant, adolescent, adult and senior stages of life in Australia

14,000+

patients are supported via AbbVie’s patient care programs in Australia

This site uses cookies to personalize content, save your preferences and track the site’s performance. Learn more, including how to disable certain cookies on our Privacy Page. Click OK to continue.